VRML : Summary for Vermillion, Inc. - Yahoo Finance

U.S. Markets open in 8 hrs 47 mins

Vermillion, Inc. (VRML)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.75+0.08 (+4.79%)
At close: 4:00PM EST
People also watch
ROSGPSDVAPPYVSTMVCYT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.67
Open1.60
Bid1.75 x 100
Ask1.80 x 200
Day's Range1.50 - 1.75
52 Week Range0.76 - 1.94
Volume74,733
Avg. Volume52,106
Market Cap91.47M
Beta1.25
PE Ratio (TTM)-5.27
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Vermillion Announces Equity Financing of $5.6 Million

    AUSTIN, Texas, Feb. 14, 2017 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company, announced today that investors, including several Vermillion directors and members of management as well as certain significant stockholders, have agreed to purchase approximately $5.6 million of unregistered shares of Vermillion's common stock and warrants to purchase unregistered shares of Vermillion's common stock in a private placement. Under the terms of the private placement, Vermillion has agreed to sell an aggregate of 3,747,125 shares of its common stock at the price of $1.40 per share, the closing price quoted on NASDAQ on February 10, 2017.

  • PR Newswirelast month

    Vermillion Announces Reimbursement Code Updates for Overa and OVA1

    AUSTIN, Texas , Jan. 9, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company, today announced that the company and its wholly owned subsidiary, ASPiRA Labs, have received ...

  • PR Newswire2 months ago

    Vermillion and ASPiRA LABS Announce Receipt of Formal FDA Clarification Regarding Ovarian Cancer Screening Alert

    AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) and ASPiRA LABS, a Vermillion company, today announced the receipt of an FDA Clarification Letter regarding OVA1 (MIA) and Overa (MIA2G).  ...